Photodynamic therapy in age-related macular degeneration with subfoveal choroidal neovascularization

Öz

Backround: The aim of this study is to investigation of the efficacy of photodynamic therapy (PDT) with verteporfin (Visudyne) and nonthermal diode laser in patients with subfoveal choroidal neovascular membrane (CNVM) on the basis of age-related macular degeneration (AMD).

Material and Methods: Patients who underwent PDT with verteporfin for subfoveal CNV due to age-related macular degeneration were included in the study. The patients were divided into two groups as the first group with classic CNVM and the second group with occult CNVM. Before and after the treatment, ocular examination of the cases with biomicroscopy was performed, fundus fluorescein angiography (FFA), visual acuity and systemic risk factors were determined. Verteporphyrin at a concentration of 2 mg / ml was given intravenously in 5% dextrose. After 15 minutes of intravenous drug administration, the non-thermal diode laser beam at a wavelength of 689 nm was applied at a dose of 50 J / cm2 for 83 seconds.

Results: A total of 37 eyes of 34 patients were included in this study. The mean age of the patients was 71.62 ± 5.2 years. Sixteen (47.05%) of the cases were female and 18 (52.94%) were male. There were only 18 eyes in the first group with classic CNVM and 19 eyes in the second group with occult CNVM. The mean ages were 71.50± 4.91 in the first group and 71.73± 5.75 in the second group. Visual acuity was increased in 3 eyes (16.6%) and in 4 eyes (21%) in Group 2. There was no systemic complication except for backache in 2 patients.

Conclusions: Photodynamic therapy with verteporfin may be an effective method in the treatment of subfoveal classic CNVM and occult type CNVM associated with AMD.

Anahtar Kelimeler

• Photodynamic therapy,Verteporfin,Age-related macular degeneration,Choroidal neovascular membrane

Subfoveal koroid neovaskülarizasyonlu yaşa bağlı maküla dejenerasyonunda fotodinamik tedavi uygulaması

Öz

Amaç: Yaşa bağlı makula dejenerasyonu (YBMD) zemininde gelişen subfoveal koroidal neovasküler membranlı (KNVM) olgularda verteporfin (Visudyne) ve non-termal diod lazer ile yapılan fotodinamik tedavinin (FDT) etkinliğinin araştırılması.

Materyal ve Metod: Yaşa bağlı maküla dejenerasyonuna bağlı olarak gelişen subfoveal KNVM için verteporfin ile FDT uygulanan hastalar çalışmaya dahil edildi. Olgular klasik KNVM’si olan olgular 1. grup ve gizli KNVM’si olan olgular ise 2. grup olmak üzere iki gruba ayrıldılar. Tedavi öncesi ve sonrasında olguların biyomikroskop ile oküler muayeneleri yapıldı, fundus floresein anjiografileri (FFA), görme keskinlikleri ve sistemik risk faktörleri belirlendi. 2 mg/ml’lik konsantrasyondaki Verteporfirin %5 dekstroz içersinde intravenöz olarak verildi. İntravenöz ilaç uygulanmasından 15 dk.sonra, 689 nm dalga boyundaki non-termal diod lazer ışını 50 J/cm2 dozunda 83 saniye uygulandı.

Bulgular: Toplamda 34 hastanın 37 gözü çalışmaya dâhil edildi. Tüm olguların yaş ortalaması 71,62±5,2 olarak bulundu. Olguların 16 ‘sı (%47,05) kadın, 18’i (% 52,94) erkek idi. Sadece klasik KNVM’si olan 1.grupta 18 göz, sadece gizli KNVM’si olan 2. grupta 19 göz bulunuyordu. Ortalama yaşlar 1. grupta 71,50± 4,91, 2.grupta 71,73± 5.75 idi. Tedavi sonrasında görme keskinliklerinde 1.grupta 3 gözde (% 16,6) 2. Grupta 4 gözde (% 21) artış görüldü. 2 hastada bel ağrısı dışında herhangi bir sistemik komlikasyon gelişmedi.

Sonuç: Verteporfirin ile fotodinamik tedavi YBMD zemininde gelişen subfoveal klasik tip KNVM’ların ve gizli tip KNVM’ların tedavisinde etkin bir yöntem olarak tercih edilebilir.

Anahtar Kelimeler

• Fotodinamik tedavi,Verteporfin,Yaşa bağlı maküla dejenerasyonu,Koroidal neovasküler membran

Kaynakça

1. 1. Fine SL, Berger JW, Maguire MG, Ho AC. Age-related macular degeneration. The New England journal of medicine. 2000;342(7):483-92.
2. 2. Bressler NM, Bressler SB, Fine SL. Age-related macular degeneration. Survey of ophthalmology. 1988;32(6):375-413.
3. 3. Klein R, Klein BE, Linton KL. Prevalence of age-related maculopathy. The Beaver Dam Eye Study. Ophthalmology. 1992;99(6):933-43.
4. 4. Klaver CC, Wolfs RC, Vingerling JR, Hofman A, de Jong PT. Age-specific prevalence and causes of blindness and visual impairment in an older population: the Rotterdam Study. Arch Ophthalmol. 1998;116(5):653-8.
5. 5. Vinding T. Age-related macular degeneration. Macular changes, prevalence and sex ratio. An epidemiological study of 1000 aged individuals. Acta ophthalmologica. 1989;67(6):609-16.
6. 6. Bressler NM, Bressler SB, Gragoudas ES. Clinical characteristics of choroidal neovascular membranes. Arch Ophthalmol. 1987;105(2):209-13.
7. 7. Risk factors for choroidal neovascularization in the second eye of patients with juxtafoveal or subfoveal choroidal neovascularization secondary to age-related macular degeneration. Macular Photocoagulation Study Group. Arch Ophthalmol. 1997;115(6):741-7.
8. 8. Interferon alfa-2a is ineffective for patients with choroidal neovascularization secondary to age-related macular degeneration. Results of a prospective randomized placebo-controlled clinical trial. Pharmacological Therapy for Macular Degeneration Study Group. Arch Ophthalmol. 1997;115(7):865-72.

9. 9. Bergink GJ, Hoyng CB, van der Maazen RW, Vingerling JR, van Daal WA, Deutman AF. A randomized controlled clinical trial on the efficacy of radiation therapy in the control of subfoveal choroidal neovascularization in age-related macular degeneration: radiation versus observation. Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie. 1998;236(5):321-5.
10. 10. Bressler NM. Submacular surgery. Are randomized trials necessary? Arch Ophthalmol. 1995;113(12):1557-60.
11. 11. Group MPS. Subfoveal neovascular lesions in age-related macular degeneration. Guidelines for evaluation and treatment in the macular photocoagulation study. Macular Photocoagulation Study Group. Arch Ophthalmol. 1991;109(9):1242-57.
12. 12. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials--TAP report. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group. Arch Ophthalmol. 1999;117(10):1329-45.
13. 13. Schmidt-Erfurth U, Miller JW, Sickenberg M, Laqua H, Barbazetto I, Gragoudas ES, et al. Photodynamic therapy with verteporfin for choroidal neovascularization caused by age-related macular degeneration: results of retreatments in a phase 1 and 2 study. Arch Ophthalmol. 1999;117(9):1177-87.
14. 14. Fine SL. Photodynamic therapy with verteporfin is effective for selected patients with neovascular age-related macular degeneration. Arch Ophthalmol. 1999;117(10):1400-2.
15. 15. Bressler NM. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-tap report 2. Arch Ophthalmol. 2001;119(2):198-207.
16. 16. Arnold J, Barbezetto I, Birngruber R, Bressler N, Bressler S, Donati G, et al. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization-verteporfin in photodynamic therapy report 2. American journal of ophthalmology. 2001;131(5):541-60.
17. 17. Reichel E, Berrocal AM, Ip M, Kroll AJ, Desai V, Duker JS, et al. Transpupillary thermotherapy of occult subfoveal choroidal neovascularization in patients with age-related macular degeneration. Ophthalmology. 1999;106(10):1908-14.
18. 18. Mainster MA, Reichel E. Transpupillary thermotherapy for age-related macular degeneration: long-pulse photocoagulation, apoptosis, and heat shock proteins. Ophthalmic Surgery, Lasers and Imaging Retina. 2000;31(5):359-73.
19. 19. Spaide RF, Guyer DR, McCormick B, Yannuzzi LA, Burke K, Mendelsohn M, et al. External beam radiation therapy for choroidal neovascularization. Ophthalmology. 1998;105(1):24-30.
20. 20. Merrill PT, LoRusso FJ, Lomeo MD, Saxe SJ, Khan MM, Lambert HM. Surgical removal of subfoveal choroidal neovascularization in age-related macular degeneration1. Ophthalmology. 1999;106(4):782-9.
21. 21. Gass J. Biomicroscopic and histopathologic considerations regarding the feasibility of surgical excision of subfoveal neovascular membranes. Transactions of the American Ophthalmological Society. 1994;92:91.
22. 22. Manyak MJ, Russo A, Smith P, Glatstein E. Photodynamic therapy. 1988.
23. 23. Husain D, Miller JW. Photodynamic therapy of exudative age-related macular degeneration. Seminars in ophthalmology. 1997;12(1):14-25.
24. 24. Husain D, Miller JW, Michaud N, Connolly E, Flotte TJ, Gragoudas ES. Intravenous infusion of liposomal benzoporphyrin derivative for photodynamic therapy of experimental choroidal neovascularization. Archives of Ophthalmology. 1996;114(8):978-85.
25. 25. Aveline B, Hasan T, Redmond RW. Photophysical and photosensitizing properties of benzoporphyrin derivative monoacid ring A (BPD‐MA). Photochemistry and photobiology. 1994;59(3):328-35.
26. 26. Allison B, Pritchard P, Levy J. Evidence for low-density lipoprotein receptor-mediated uptake of benzoporphyrin derivative. British journal of cancer. 1994;69(5):833.
27. 27. Husain D, Kramer M, Kenny AG, Michaud N, Flotte TJ, Gragoudas ES, et al. Effects of photodynamic therapy using verteporfin on experimental choroidal neovascularization and normal retina and choroid up to 7 weeks after treatment. Investigative ophthalmology & visual science. 1999;40(10):2322-31.